IL-2/B7.1 fusagene transduction of AML blasts by a self-inactivating lentiviral vector stimulates T cell responses in vitro: A strategy to generate whole cell vaccines for AML

IL-2/B7.1 fusagene transduction of AML blasts by a self-inactivating lentiviral vector stimulates T cell responses in vitro: A strategy to generate whole cell vaccines for AML

Dettagli Bibliografici
Autori principali:	Chan, L, Hardwick, N, Darling, D, Galea-Lauri, J, Gaken, J, Devereux, S, Kemeny, M, Mufti, G, Farzaneh, F
Natura:	Journal article
Pubblicazione:	2004

Documenti analoghi

IL-2/B7.1 (CD80) fusagene transduction of AML blasts by a self-inactivating lentiviral vector stimulates T cell responses in vitro: a strategy to generate whole cell vaccines for AML.
di: Chan, L, et al.
Pubblicazione: (2005)

Transduction of Primary AML Cells with Lentiviral Vector for In Vitro Study or In Vivo Engraftment
di: Aaron D. Schimmer, et al.
Pubblicazione: (2020-12-01)

Fusagene vectors: A novel strategy for the expression of multiple genes from a single cistron
di: Gaken, J, et al.
Pubblicazione: (1998)

Fusagene vectors: a novel strategy for the expression of multiple genes from a single cistron.
di: Gäken, J, et al.
Pubblicazione: (2000)

Fusagene vectors: a novel strategy for the expression of multiple genes from a single cistron
di: Gaken, J, et al.
Pubblicazione: (2001)

Tumour cells expressing B7.1 costimulatory molecule: Are these better targets for NK cells?
di: GaleaLauri, J, et al.
Pubblicazione: (1996)

Induction of tumour rejection by autologous and allogeneic tumour cells expressing B7.1 and IL-2.
di: Hirst, W, et al.
Pubblicazione: (1996)

Induction of tumour rejection by B7.1 and IL-2 expressing tumour cells
di: Gaken, J, et al.
Pubblicazione: (1997)

Preclinical validation: LV/IL-12 transduction of patient leukemia cells for immunotherapy of AML
di: Ju Huang, et al.
Pubblicazione: (2016-01-01)

TREATMENT OF LOW-BLAST COUNT AML USING HYPOMETHYLATING AGENTS
di: Eleonora De Bellis, et al.
Pubblicazione: (2017-07-01)

Monocistronic high titre vectors for targeted expression of multiple therapeutic genes
di: Darling, D, et al.
Pubblicazione: (2004)

High titre vectors for targeted expression of multiple genes
di: Darling, D, et al.
Pubblicazione: (2004)

Comparative analysis of extracellular vesicle isolation methods from human AML bone marrow cells and AML cell lines
di: Jonas B. Lang, et al.
Pubblicazione: (2022-10-01)

Irradiated NC adenocarcinoma cells transduced with both B7.1 and interleukin-2 induce CD4+-mediated rejection of established tumors.
di: Gaken, J, et al.
Pubblicazione: (1997)

The Metabolic Signature of AML Cells Treated With Homoharringtonine
di: Yulong Zhang, et al.
Pubblicazione: (2022-06-01)

MEIS2 Is an Oncogenic Partner in AML1-ETO-Positive AML
di: Naidu M. Vegi, et al.
Pubblicazione: (2016-07-01)

Automated and closed clinical-grade manufacturing protocol produces potent NK cells against neuroblastoma cells and AML blasts
di: Farhana Jahan, et al.
Pubblicazione: (2024-11-01)

AML1/ETO oncoprotein is directed to AML1 binding regions and co-localizes with AML1 and HEB on its targets.
di: Alessandro Gardini, et al.
Pubblicazione: (2008-11-01)

Prospects of immune gene therapy for cancer
di: Hardwick, N, et al.
Pubblicazione: (2004)

MicroRNA-mRNA Pairs Associated with Outcome in AML: From in vitro Cell-based Studies to AML Patients
di: Neha S Bhise, et al.
Pubblicazione: (2016-01-01)

Cytoplasmic NEAT1 Suppresses AML Stem Cell Self‐Renewal and Leukemogenesis through Inactivation of Wnt Signaling
di: Huiwen Yan, et al.
Pubblicazione: (2021-11-01)

An immune edited tumour versus a tumour edited immune system: Prospects for immune therapy of acute myeloid leukaemia.
di: Chan, L, et al.
Pubblicazione: (2006)

Abolishing Retro-Transduction of Producer Cells in Lentiviral Vector Manufacturing
di: Soledad Banos-Mateos, et al.
Pubblicazione: (2024-07-01)

Identification of a small molecule for enhancing lentiviral transduction of T cells
di: Paulina Malach, et al.
Pubblicazione: (2023-12-01)

Biomarkers as targets for CAR-T/NK cell therapy in AML
di: Ruonan Shao, et al.
Pubblicazione: (2023-06-01)

Chimeric antigen receptor T-cell therapy for T-ALL and AML
di: Wenwen Wei, et al.
Pubblicazione: (2022-11-01)

P577: 20% BLAST CRITERIA FOR DIAGNOSING AML/MDS: IS IT TIME TO MOVE BEYOND?
di: V. Sheth, et al.
Pubblicazione: (2022-06-01)

Type I interferon signaling in malignant blasts contributes to treatment efficacy in AML patients
di: Peter Holicek, et al.
Pubblicazione: (2023-03-01)

8-Hydroxydaidzein Induces Apoptosis and Inhibits AML-Associated Gene Expression in U-937 Cells: Potential Phytochemical for AML Treatment
di: Pei-Shan Wu, et al.
Pubblicazione: (2023-10-01)

Alteration of T cell immunity by lentiviral transduction of human monocyte-derived dendritic cells
di: Chang Lung-Ji, et al.
Pubblicazione: (2004-11-01)

P1309: DYSREGULATED EXPRESSIONS OF INHIBITORY CHECKPOINT MOLECULES AND THEIR LIGANDS ON T-CELLS AND BLASTS IN AML RELAPSES AFTER STEM CELL TRANSPLANTATION (SCT)
di: S. Bohlscheid, et al.
Pubblicazione: (2022-06-01)

P1350: M2-LIKE MONOCYTE-DERIVED MACROPHAGES PROTECT AML CELL LINES AND PRIMARY AML CELLS AGAINST THERAPY-INDUCED APOPTOSIS
di: Katerina Miari, et al.
Pubblicazione: (2023-08-01)

THE CHALLENGE OF AML IN OLDER PATIENTS
di: Alan K Burnett
Pubblicazione: (2013-06-01)

The Evolving Treatment Landscape of AML
di: Sabine Blum, et al.
Pubblicazione: (2022-03-01)

Maintenance of telomere length in AML
di: Peter M. Lansdorp
Pubblicazione: (2017-11-01)

Inherited predisposition to MDS/AML
di: Ana Rio Machin, et al.
Pubblicazione: (2018-06-01)

The Evolving Treatment Landscape of AML
di: Sabine Blum, et al.
Pubblicazione: (2022-03-01)

Emerging agents and regimens for AML
di: Hongtao Liu
Pubblicazione: (2021-03-01)

TARGETED THERAPY IN AML TREATMENT
di: Giovanni Martinelli
Pubblicazione: (2021-11-01)

ELMO1 is upregulated in AML CD34+ stem/progenitor cells, mediates chemotaxis and predicts poor prognosis in normal karyotype AML.
di: Marta E Capala, et al.
Pubblicazione: (2014-01-01)